Tim Anderson, an analyst at Sanford Bernstein, believes the FDA is struggling with the North American findings and it remains to be seen how much weight will be given to them.
"If they are weighted heavily and there is felt to be no easy explanation, then Brilinta's approvability might be at risk," he said.
With consensus 2014 sales forecasts for Brilinta standing at $1.1 billion, according to Thomson Reuters data, and the drug central to AstraZeneca's strategy for overcoming patent losses, a lot is riding on next week's panel.
via reuters.com
No comments:
Post a Comment